Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (71-80 of 492) with videos related to

Pageof 50
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
Horizon scanning for novel therapeutics for the treatment of prostate cancerD Bianchini, A Zivi, S Sandhu, et al.
Expert Review of Anticancer Therapy|October 27, 2012
Cabazitaxel in metastatic castration-resistant prostate cancerTimothy A Yap, Carmel J Pezaro, Johann S de Bono
European Journal of Cancer (Oxford, England : 1990)|November 21, 2009
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspectiveShahneen K Sandhu, Timothy A Yap, Johann S de Bono
Breast Cancer Research : BCR|June 10, 2003
The future of cytotoxic therapy: selective cytotoxicity based on biology is the keyJohann S de Bono, Anthony W Tolcher, Eric K Rowinsky
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 25, 2015
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitorsA Stewart, P Thavasu, J S de Bono, et al.
Current Drug Targets|July 23, 2011
The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatmentShahneen K Sandhu, Timothy A Yap, Johann S de Bono
Cancer Journal (Sudbury, Mass.)|October 18, 2016
Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate CancerElena Castro, Joaquin Mateo, David Olmos, et al.
Journal of Clinical Pathology|May 23, 2008
Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug developmentG Attard, J E Ang, D Olmos, et al.
Nature Reviews. Clinical Oncology|August 10, 2011
The changing therapeutic landscape of castration-resistant prostate cancerTimothy A Yap, Andrea Zivi, Aurelius Omlin, et al.
Cancer Treatment Reviews|January 8, 2013
New treatment developments applied to elderly patients with advanced prostate cancerDeborah Mukherji, Carmel J Pezaro, Ali Shamseddine, et al.
Pageof 50

Showing results (71-80 of 492) with videos related to

Sort By:
Pageof 50
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
Horizon scanning for novel therapeutics for the treatment of prostate cancerD Bianchini, A Zivi, S Sandhu, et al.
Expert Review of Anticancer Therapy|October 27, 2012
Cabazitaxel in metastatic castration-resistant prostate cancerTimothy A Yap, Carmel J Pezaro, Johann S de Bono
European Journal of Cancer (Oxford, England : 1990)|November 21, 2009
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspectiveShahneen K Sandhu, Timothy A Yap, Johann S de Bono
Breast Cancer Research : BCR|June 10, 2003
The future of cytotoxic therapy: selective cytotoxicity based on biology is the keyJohann S de Bono, Anthony W Tolcher, Eric K Rowinsky
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 25, 2015
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitorsA Stewart, P Thavasu, J S de Bono, et al.
Current Drug Targets|July 23, 2011
The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatmentShahneen K Sandhu, Timothy A Yap, Johann S de Bono
Cancer Journal (Sudbury, Mass.)|October 18, 2016
Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate CancerElena Castro, Joaquin Mateo, David Olmos, et al.
Journal of Clinical Pathology|May 23, 2008
Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug developmentG Attard, J E Ang, D Olmos, et al.
Nature Reviews. Clinical Oncology|August 10, 2011
The changing therapeutic landscape of castration-resistant prostate cancerTimothy A Yap, Andrea Zivi, Aurelius Omlin, et al.
Cancer Treatment Reviews|January 8, 2013
New treatment developments applied to elderly patients with advanced prostate cancerDeborah Mukherji, Carmel J Pezaro, Ali Shamseddine, et al.
Pageof 50